X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7470) 7470
Book Review (896) 896
Publication (606) 606
Book Chapter (31) 31
Conference Proceeding (18) 18
Magazine Article (10) 10
Book / eBook (8) 8
Dissertation (3) 3
Newsletter (2) 2
Trade Publication Article (2) 2
Data Set (1) 1
Reference (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (6489) 6489
humans (3719) 3719
animals (3680) 3680
male (2992) 2992
adenine - analogs & derivatives (2818) 2818
female (2096) 2096
rats (1761) 1761
tenofovir (1396) 1396
adenine - administration & dosage (1334) 1334
adult (1214) 1214
adenine - therapeutic use (1095) 1095
pharmacology & pharmacy (1022) 1022
adenine - pharmacology (999) 999
mice (993) 993
adenine (989) 989
middle aged (969) 969
organophosphonates - administration & dosage (962) 962
organophosphonates - therapeutic use (806) 806
hiv infections - drug therapy (801) 801
biochemistry & molecular biology (684) 684
adenine nucleotides - metabolism (668) 668
infectious diseases (653) 653
treatment outcome (628) 628
anti-hiv agents - administration & dosage (595) 595
drug therapy, combination (589) 589
metabolism (578) 578
adenine - adverse effects (557) 557
oxidative stress (552) 552
abridged index medicus (537) 537
time factors (530) 530
research (529) 529
antiviral agents - therapeutic use (505) 505
immunology (500) 500
cell biology (496) 496
analysis (493) 493
hepatitis b, chronic - drug therapy (480) 480
apoptosis (466) 466
anti-hiv agents - therapeutic use (460) 460
emtricitabine (460) 460
deoxycytidine - analogs & derivatives (448) 448
dose-response relationship, drug (443) 443
organophosphonates - adverse effects (437) 437
hiv (416) 416
proteins (409) 409
health aspects (407) 407
aged (399) 399
drug therapy (397) 397
antiviral agents - administration & dosage (395) 395
lamivudine (393) 393
liver - metabolism (390) 390
rats, sprague-dawley (390) 390
physiology (383) 383
neurosciences (382) 382
physiological aspects (379) 379
nicotinamide adenine dinucleotide (376) 376
rodents (376) 376
rats, wistar (371) 371
virology (371) 371
article (369) 369
aids/hiv (364) 364
therapy (364) 364
enzymes (359) 359
in vitro techniques (353) 353
mitochondria (350) 350
medicine (348) 348
oncology (347) 347
multidisciplinary sciences (346) 346
disease models, animal (341) 341
lamivudine - therapeutic use (341) 341
adenosine triphosphate - metabolism (336) 336
research article (332) 332
cancer (330) 330
liver (323) 323
cells (318) 318
mutation (318) 318
deoxycytidine - administration & dosage (316) 316
inhibition (308) 308
anti-hiv agents - adverse effects (307) 307
adolescent (305) 305
human immunodeficiency virus--hiv (305) 305
infection (305) 305
hepatitis b (301) 301
gastroenterology & hepatology (300) 300
adenine - pharmacokinetics (297) 297
organophosphonates (295) 295
nad (288) 288
antiviral agents (287) 287
viral load (286) 286
reverse transcriptase inhibitors - administration & dosage (285) 285
cells, cultured (284) 284
adenosine (283) 283
purines (283) 283
activation (280) 280
young adult (277) 277
adenine - metabolism (275) 275
expression (275) 275
drug administration schedule (272) 272
lamivudine - administration & dosage (272) 272
dosage and administration (268) 268
myocardium - metabolism (268) 268
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7192) 7192
Russian (65) 65
German (61) 61
Japanese (38) 38
Chinese (37) 37
Spanish (36) 36
French (31) 31
Italian (13) 13
Korean (8) 8
Hungarian (5) 5
Polish (5) 5
Ukrainian (5) 5
Slovak (4) 4
Dutch (3) 3
Czech (2) 2
Bulgarian (1) 1
Hebrew (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9835, pp. 2429 - 2438
Summary Background The HIV integrase strand transfer inhibitor elvitegravir (EVG) has been co-formulated with the CYP3A4 inhibitor cobicistat (COBI),... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | PHARMACOKINETICS | SAFETY | NAIVE HIV-1-INFECTED PATIENTS | TREATMENT-EXPERIENCED PATIENTS | EFAVIRENZ | ADULTS | ANTIRETROVIRAL THERAPY | SINGLE-TABLET REGIMEN | PATIENTS 96-WEEK EFFICACY | COMBINATION | HIV-1 | Humans | Middle Aged | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Anti-HIV Agents - administration & dosage | Tenofovir | Atazanavir Sulfate | Adult | Female | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Double-Blind Method | Ritonavir - administration & dosage | Deoxycytidine - administration & dosage | Adenine - administration & dosage | Organophosphonates - administration & dosage | Quinolones - administration & dosage | HIV Infections - drug therapy | Oligopeptides - administration & dosage | Cobicistat | Deoxycytidine - analogs & derivatives | Drug Combinations | Antiviral agents | Patient outcomes | Dosage and administration | Research | Comparative analysis | Drug therapy | HIV infection | Anti-HIV agents | Antiretroviral drugs | Bone density | Pharmaceutical industry | Human immunodeficiency virus--HIV | Pneumonia | Laboratories | Ritonavir | Liver | Infections | Drug resistance | Hepatitis | Randomization | All terrain vehicles | Creatinine | Integrase | Data processing | Proteinase inhibitors | Behavior disorders | Ribonucleic acid--RNA | Patients | Cholesterol | Glomerular filtration rate | Inhibitors | Protease inhibitors | Interactive systems | Index Medicus | Abridged Index Medicus
Journal Article
Science, ISSN 0036-8075, 9/2010, Volume 329, Issue 5996, pp. 1168 - 1174
The Centre for the AIDS Program of Research in South Africa (CAPRISA) 004 trial assessed the effectiveness and safety of a 1% vaginal gel formulation of... 
Human sexual behavior | HIV infections | Antiinfectives | Gels | HIV | RESEARCH ARTICLES | Placebos | Experimentation | AIDS | Infections | Condoms | VAGINAL GEL | INDIVIDUALS | SOUTH-AFRICA | PROPHYLAXIS | IN-VITRO | TRANSMISSION | MULTIDISCIPLINARY SCIENCES | CLINICAL-TRIALS | MALE CIRCUMCISION | RANDOMIZED CONTROLLED-TRIAL | CHALLENGES | HIV Infections - prevention & control | Anti-Infective Agents, Local - therapeutic use | Urban Population - statistics & numerical data | HIV Infections - epidemiology | Humans | Anti-Infective Agents, Local - adverse effects | Drug Resistance, Viral | Administration, Intravaginal | Viral Load | Incidence | Anti-HIV Agents - administration & dosage | Tenofovir | Young Adult | Adenine - adverse effects | HIV-1 - physiology | Adenine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Vaginal Creams, Foams, and Jellies | Rural Population - statistics & numerical data | Sexual Behavior | Adenine - analogs & derivatives | Double-Blind Method | Organophosphonates - therapeutic use | HIV-1 - drug effects | Anti-HIV Agents - adverse effects | South Africa - epidemiology | Organophosphonates - adverse effects | Adenine - administration & dosage | Pregnancy | Organophosphonates - administration & dosage | Anti-Infective Agents, Local - administration & dosage | Adolescent | Patient Compliance | Pregnancy Outcome | Prevention | Anti-infective agents | Research | HIV infection | Index Medicus
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 08/2012, Volume 74, Issue 2, pp. 336 - 345
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • In healthy subjects, GSK2248761 was shown to be safe and well tolerated with single doses up to 1200 mg once daily... 
NNRTI | HIV‐1 infection | antiretroviral therapy | drug‐drug interaction | HIV-1 infection | Drug-drug interaction | Antiretroviral therapy | PHARMACOKINETICS | TOLERABILITY | PHARMACOLOGY & PHARMACY | ATAZANAVIR | SIMVASTATIN | drug-drug interaction | PROTEASE INHIBITORS | Fluorobenzenes - pharmacokinetics | Pyrroles - pharmacokinetics | Darunavir | Ethinyl Estradiol - pharmacokinetics | Humans | Pyrrolidinones - pharmacokinetics | Male | Fluorobenzenes - administration & dosage | Indoles - administration & dosage | Lopinavir - pharmacokinetics | Anti-HIV Agents - administration & dosage | Pyrrolidinones - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | Drug Interactions | Pyrroles - administration & dosage | Contraceptives, Oral - administration & dosage | Patient Safety | Atazanavir Sulfate | Contraceptives, Oral - pharmacokinetics | Phosphinic Acids - administration & dosage | Raltegravir Potassium | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Risk Assessment | Simvastatin - administration & dosage | Deoxycytidine - administration & dosage | Phosphinic Acids - pharmacokinetics | Rosuvastatin Calcium | Adenine - pharmacokinetics | Sulfonamides - pharmacokinetics | Cross-Over Studies | Cytochrome P-450 CYP3A - metabolism | Atorvastatin | Cytochrome P-450 CYP2D6 - metabolism | Least-Squares Analysis | Lopinavir - administration & dosage | Pyrimidines - pharmacokinetics | Oligopeptides - administration & dosage | Deoxycytidine - analogs & derivatives | Sulfonamides - administration & dosage | Cytochrome P-450 CYP2D6 Inhibitors | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Heptanoic Acids - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics | Reverse Transcriptase Inhibitors - pharmacokinetics | Heptanoic Acids - administration & dosage | Female | Ethinyl Estradiol - administration & dosage | Androstenes - pharmacokinetics | Double-Blind Method | Ritonavir - administration & dosage | Pyrimidines - administration & dosage | Oligopeptides - pharmacokinetics | Linear Models | Simvastatin - pharmacokinetics | Androstenes - administration & dosage | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Cytochrome P-450 CYP3A Inhibitors | Ritonavir - pharmacokinetics | Anti-HIV Agents - pharmacokinetics | Indoles - pharmacokinetics | Drug Combinations | Urine | Simvastatin | Drug interactions | Cytochrome P-450 | HIV (Viruses) | Complications and side effects | Analysis | Electrocardiogram | Electrocardiography | DNA polymerases | Ethinyl estradiol | Dosage and administration | Index Medicus | EKG | Antiviral agents | Urinalysis | Ritonavir | tenofovir | Cytochrome P450 | Lopinavir | ethinylestradiol | Blood | Infection | non-nucleoside reverse transcriptase inhibitors | Antiviral activity | Drug interaction | Probes | CYP2D6 protein
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 7/2013, Volume 208, Issue 1, pp. 32 - 39
Background. Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity in vitro. Methods. An international, randomized, double-blind,... 
T lymphocytes | HIV/AIDS | Antiretrovirals | Infectious diseases | RNA | HIV | Drug evaluation | AIDS | Photographs | HIV 1 | Virology | cobicistat | pharmacoenhancer | INFECTIOUS DISEASES | CO-FORMULATED ELVITEGRAVIR | RENAL-FUNCTION | INITIAL TREATMENT | MICROBIOLOGY | HIV-1-INFECTED PATIENTS | IMMUNOLOGY | DAILY LOPINAVIR/RITONAVIR | GLOMERULAR-FILTRATION-RATE | EFAVIRENZ | DOUBLE-BLIND | ONCE-DAILY DARUNAVIR/RITONAVIR | TENOFOVIR | Humans | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Thiazoles - therapeutic use | Oligopeptides - therapeutic use | Anti-HIV Agents - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Adenine - therapeutic use | Atazanavir Sulfate | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Female | Drug Therapy, Combination | Pyridines - therapeutic use | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Double-Blind Method | Organophosphonates - therapeutic use | Ritonavir - administration & dosage | HIV-1 - drug effects | Deoxycytidine - administration & dosage | Treatment Outcome | HIV Protease Inhibitors - administration & dosage | HIV Protease Inhibitors - therapeutic use | Adenine - administration & dosage | Organophosphonates - administration & dosage | HIV Infections - drug therapy | Oligopeptides - administration & dosage | Carbamates - therapeutic use | Viral Load - drug effects | Cobicistat | Deoxycytidine - analogs & derivatives | Research | Drug therapy | HIV infection | Patient outcomes | Index Medicus | Abridged Index Medicus
Journal Article
AIDS, ISSN 0269-9370, 09/2007, Volume 21, Issue 14, pp. 1899 - 1907
Objectives: To describe first dose and steady state antiretroviral drug exposure in the female genital tract. Design: Non-blinded, single center, open-label... 
Women | Genital tract | HIV | Prophylaxis | Sexual transmission | Pharmacokinetics | Antiretroviral therapy | genital tract | INFECTIOUS DISEASES | sexual transmission | antiretroviral therapy | EMTRICITABINE | IMMUNOLOGY | CEREBROSPINAL-FLUID | prophylaxis | BACTERIAL VAGINOSIS | PROTEASE INHIBITOR | TRICHOMONAS-VAGINALIS | HIV-INFECTION | THERAPY | VIROLOGY | LIQUID-CHROMATOGRAPHY | SIMIAN IMMUNODEFICIENCY VIRUS | pharmacokinetics | MACAQUES | women | Lamivudine - administration & dosage | Humans | Deoxycytidine - blood | Zidovudine - administration & dosage | Tenofovir | Deoxycytidine - pharmacokinetics | HIV Protease Inhibitors - pharmacokinetics | Atazanavir Sulfate | Genitalia, Female - metabolism | Emtricitabine | HIV Infections - blood | HIV Protease Inhibitors - blood | Adenine - analogs & derivatives | Pyridines - administration & dosage | Benzoxazines - administration & dosage | Administration, Oral | Anti-Retroviral Agents - pharmacokinetics | Deoxycytidine - administration & dosage | Lopinavir | HIV Protease Inhibitors - administration & dosage | Adenine - pharmacokinetics | Pyrimidinones - blood | Anti-Retroviral Agents - administration & dosage | Oligopeptides - administration & dosage | Pyrimidinones - administration & dosage | Zidovudine - blood | Deoxycytidine - analogs & derivatives | Reverse Transcriptase Inhibitors - blood | Zidovudine - pharmacokinetics | Pyridines - pharmacokinetics | Reverse Transcriptase Inhibitors - administration & dosage | Adenine - blood | Reverse Transcriptase Inhibitors - pharmacokinetics | Benzoxazines - pharmacokinetics | Adult | Benzoxazines - blood | Female | Organophosphonates - blood | Anti-Retroviral Agents - blood | Drug Therapy, Combination | Oligopeptides - blood | Oligopeptides - pharmacokinetics | Lamivudine - blood | Lamivudine - pharmacokinetics | Adenine - administration & dosage | Organophosphonates - pharmacokinetics | Organophosphonates - administration & dosage | Pyridines - blood | Pyrimidinones - pharmacokinetics | HIV Infections - drug therapy | Index Medicus | AIDS/HIV
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9835, pp. 2439 - 2448
Summary Background The integrase inhibitor elvitegravir (EVG) has been co-formulated with the CYP3A4 inhibitor cobicistat (COBI), emtricitabine (FTC), and... 
Internal Medicine | NON-INFERIORITY | LAMIVUDINE | MEDICINE, GENERAL & INTERNAL | RALTEGRAVIR | TREATMENT-EXPERIENCED PATIENTS | DISOPROXIL FUMARATE | ADULTS | ANTIRETROVIRAL THERAPY | SINGLE-TABLET REGIMEN | RILPIVIRINE | TREATMENT-NAIVE PATIENTS | Emtricitabine | HIV-1 | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Deoxycytidine - administration & dosage | Humans | Middle Aged | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Adenine - administration & dosage | Anti-HIV Agents - administration & dosage | Tenofovir | Organophosphonates - administration & dosage | Quinolones - administration & dosage | Adult | Female | HIV Infections - drug therapy | Cobicistat | Deoxycytidine - analogs & derivatives | Drug Combinations | Antiviral agents | Patient outcomes | Dosage and administration | Research | Comparative analysis | Drug therapy | HIV infection | Anti-HIV agents | Clinical trials | Antiretroviral drugs | Pharmaceutical industry | Human immunodeficiency virus--HIV | Creatinine | Integrase | Laboratories | Data processing | Infections | Nausea | Ribonucleic acid--RNA | Patients | Efavirenz | Dreams | Sleep disorders | Hepatitis | Dyspnea | Inhibitors | Protease inhibitors | Insomnia | Suicides & suicide attempts | Index Medicus | Abridged Index Medicus
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 08/2008, Volume 52, Issue 7, pp. 569 - 576
Objectives: This study evaluated the effects of 3 class-sparing antiretroviral therapy (ART) regimens on endothelial function in human immunodeficiency virus... 
endothelial function | human immunodeficiency virus | cardiovascular disease risk | antiretroviral therapy | CELLS | CARDIAC & CARDIOVASCULAR SYSTEMS | EVENTS | MYOCARDIAL-INFARCTION | GUIDELINES | TASK-FORCE | DISEASE | DYSFUNCTION | HIV-1 INFECTION | CARDIOVASCULAR RISK | RITONAVIR | HIV-1 | Lamivudine - administration & dosage | Prospective Studies | Humans | Endothelium, Vascular - drug effects | Male | Stavudine - administration & dosage | Reverse Transcriptase Inhibitors - administration & dosage | Zidovudine - administration & dosage | Anti-HIV Agents - administration & dosage | Tenofovir | Time Factors | Adult | Brachial Artery - physiopathology | Female | Brachial Artery - drug effects | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Ritonavir - administration & dosage | Lopinavir | CD4 Lymphocyte Count | HIV Protease Inhibitors - administration & dosage | Adenine - administration & dosage | Organophosphonates - administration & dosage | Endothelium, Vascular - pathology | HIV Infections - drug therapy | Pyrimidinones - administration & dosage | HIV Infections - physiopathology | Studies | Ultrasonic imaging | Human immunodeficiency virus--HIV | Deflation | Aging | Clinical trials | Infections | Diabetes | Drug therapy | Risk factors | Cholesterol | Veins & arteries | Index Medicus | Abridged Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9787, pp. 238 - 246
Summary Background Efavirenz with tenofovir-disoproxil-fumarate and emtricitabine is a preferred antiretroviral regimen for treatment-naive patients infected... 
Internal Medicine | LAMIVUDINE | MEDICINE, GENERAL & INTERNAL | EFFICACY | SAFETY | COMBINATION THERAPY | GUIDELINES | PROTEASE-INHIBITOR | ANTIRETROVIRAL THERAPY | NEVIRAPINE | REGIMENS | Rilpivirine | HIV Reverse Transcriptase - antagonists & inhibitors | Humans | Middle Aged | Male | Anti-HIV Agents - administration & dosage | Nitriles - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Adenine - adverse effects | Adenine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Reverse Transcriptase Inhibitors - therapeutic use | Acquired Immunodeficiency Syndrome - virology | Acquired Immunodeficiency Syndrome - ethnology | Emtricitabine | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Organophosphonates - therapeutic use | HIV-1 - drug effects | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | Organophosphonates - adverse effects | Benzoxazines - adverse effects | Treatment Outcome | HIV-1 - genetics | Acquired Immunodeficiency Syndrome - drug therapy | Adenine - administration & dosage | Benzoxazines - therapeutic use | Organophosphonates - administration & dosage | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Aged | Mutation | Nitriles - adverse effects | Viral Load - drug effects | Deoxycytidine - analogs & derivatives | Nitriles - therapeutic use | Dosage and administration | Efavirenz | Patient outcomes | Clinical trials | Antiretroviral drugs | Drug therapy | Human immunodeficiency virus--HIV | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2015, Volume 372, Issue 6, pp. 509 - 518
Preventing HIV-1 infection is a high global priority. This study assessed prevention strategies in young women in South Africa, Uganda, and Zimbabwe using oral... 
TRIALS | MEDICINE, GENERAL & INTERNAL | TRANSMISSION | ANTIRETROVIRAL PROPHYLAXIS | MICROBICIDE | PREVENTION | ADHERENCE | GEL | HIV Infections - prevention & control | Humans | Middle Aged | Drug Resistance, Viral | Administration, Intravaginal | Deoxycytidine - blood | Adenine - blood | Tenofovir | Young Adult | Adenine - adverse effects | Adult | Deoxycytidine - adverse effects | Female | Organophosphonates - blood | Surveys and Questionnaires | Anti-Retroviral Agents - blood | Drug Therapy, Combination | Emtricitabine | Adenine - analogs & derivatives | HIV Seropositivity | Administration, Oral | HIV-1 - drug effects | Deoxycytidine - administration & dosage | Anti-Retroviral Agents - adverse effects | Organophosphonates - adverse effects | Africa South of the Sahara | Adenine - administration & dosage | Pre-Exposure Prophylaxis | Organophosphonates - administration & dosage | Medication Adherence | Anti-Retroviral Agents - administration & dosage | Adolescent | HIV Infections - complications | Deoxycytidine - analogs & derivatives | Women | Care and treatment | HIV infection in women | Dosage and administration | HIV infection | Health aspects | Risk factors | Intervention | Creatinine | Antiretroviral drugs | Motivation | Human immunodeficiency virus--HIV | Prophylaxis | Vagina | Infections | Preventive medicine | Index Medicus | Abridged Index Medicus
Journal Article